Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 93

1.

Identification of New Mono/Dihydroxynaphthoquinone as Lead Agents That Inhibit the Growth of Refractive and Triple-Negative Breast Cancer Cell Lines.

Schroeder R, Sfondouris M, Goyal N, Komati R, Weerathunga A, Gettridge C, Stevens CLK, Jones FE, Sridhar J.

ACS Omega. 2019 Jun 19;4(6):10610-10619. doi: 10.1021/acsomega.9b00929. eCollection 2019 Jun 30.

2.

4-Sodium phenyl butyric acid has both efficacy and counter-indicative effects in the treatment of Col4a1 disease.

Jones FE, Murray LS, McNeilly S, Dean A, Aman A, Lu Y, Nikolova N, Malomgré R, Horsburgh K, Holmes WM, Kadler KE, Van Agtmael T.

Hum Mol Genet. 2019 Feb 15;28(4):628-638. doi: 10.1093/hmg/ddy369.

3.

Ablating ErbB4 in PV neurons attenuates synaptic and cognitive deficits in an animal model of Alzheimer's disease.

Zhang H, Zhang L, Zhou D, He X, Wang D, Pan H, Zhang X, Mei Y, Qian Q, Zheng T, Jones FE, Sun B.

Neurobiol Dis. 2017 Oct;106:171-180. doi: 10.1016/j.nbd.2017.07.001. Epub 2017 Jul 4.

PMID:
28684271
4.

Trastuzumab stimulation of ribosomal protein S6 kinase 1 (S6K1) predicts de novo trastuzumab resistance.

Huynh FC, Nguyen D, Jones FE.

Biochem Biophys Res Commun. 2017 Jan 29;483(1):739-744. doi: 10.1016/j.bbrc.2016.12.072. Epub 2016 Dec 18.

PMID:
27993682
5.

Intrinsic HER4/4ICD transcriptional activation domains are required for STAT5A activated gene expression.

Han W, Sfondouris ME, Semmes EC, Meyer AM, Jones FE.

Gene. 2016 Oct 30;592(1):221-226. doi: 10.1016/j.gene.2016.07.071. Epub 2016 Aug 5.

PMID:
27502417
6.

Direct coupling of the HER4 intracellular domain (4ICD) and STAT5A signaling is required to induce mammary epithelial cell differentiation.

Han W, Sfondouris ME, Jones FE.

Biochem Biophys Rep. 2016 Jul 20;7:323-327. doi: 10.1016/j.bbrep.2016.07.015. eCollection 2016 Sep.

7.

The transcription factor NeuroD2 coordinates synaptic innervation and cell intrinsic properties to control excitability of cortical pyramidal neurons.

Chen F, Moran JT, Zhang Y, Ates KM, Yu D, Schrader LA, Das PM, Jones FE, Hall BJ.

J Physiol. 2016 Jul 1;594(13):3729-44. doi: 10.1113/JP271953.

8.

ER stress and basement membrane defects combine to cause glomerular and tubular renal disease resulting from Col4a1 mutations in mice.

Jones FE, Bailey MA, Murray LS, Lu Y, McNeilly S, Schlötzer-Schrehardt U, Lennon R, Sado Y, Brownstein DG, Mullins JJ, Kadler KE, Van Agtmael T.

Dis Model Mech. 2016 Feb;9(2):165-76. doi: 10.1242/dmm.021741.

9.

MicroRNA-7 inhibits multiple oncogenic pathways to suppress HER2Δ16 mediated breast tumorigenesis and reverse trastuzumab resistance.

Huynh FC, Jones FE.

PLoS One. 2014 Dec 22;9(12):e114419. doi: 10.1371/journal.pone.0114419. eCollection 2014.

10.

A class of genes in the HER2 regulon that is poised for transcription in breast cancer cell lines and expressed in human breast tumors.

Rahmatpanah FB, Jia Z, Chen X, Char JE, Men B, Franke AC, Jones FE, McClelland M, Mercola D.

Oncotarget. 2015 Jan 20;6(2):1286-301.

11.

Hypoxia-inducible factor-1α induces ErbB4 signaling in the differentiating mammary gland.

Paatero I, Seagroves TN, Vaparanta K, Han W, Jones FE, Johnson RS, Elenius K.

J Biol Chem. 2014 Aug 8;289(32):22459-69. doi: 10.1074/jbc.M113.533497. Epub 2014 Jun 25.

12.

Basal cell signaling by p63 controls luminal progenitor function and lactation via NRG1.

Forster N, Saladi SV, van Bragt M, Sfondouris ME, Jones FE, Li Z, Ellisen LW.

Dev Cell. 2014 Jan 27;28(2):147-60. doi: 10.1016/j.devcel.2013.11.019. Epub 2014 Jan 9.

13.

Identification of quinones as HER2 inhibitors for the treatment of trastuzumab resistant breast cancer.

Sridhar J, Sfondouris ME, Bratton MR, Nguyen TL, Townley I, Klein Stevens CL, Jones FE.

Bioorg Med Chem Lett. 2014 Jan 1;24(1):126-31. doi: 10.1016/j.bmcl.2013.11.064. Epub 2013 Dec 3.

PMID:
24355130
14.

HER4 selectively coregulates estrogen stimulated genes associated with breast tumor cell proliferation.

Han W, Jones FE.

Biochem Biophys Res Commun. 2014 Jan 10;443(2):458-63. doi: 10.1016/j.bbrc.2013.11.111. Epub 2013 Dec 11.

15.

A study of host corneal endothelial cells after non-Descemet stripping automated endothelial keratoplasty.

Hatanaka H, Koizumi N, Okumura N, Takahashi H, Tanioka H, Young RD, Jones FE, Quantock AJ, Kinoshita S.

Cornea. 2013 Jan;32(1):76-80. doi: 10.1097/ICO.0b013e31825d568a.

PMID:
22968356
16.

Interaction with ErbB4 promotes hypoxia-inducible factor-1α signaling.

Paatero I, Jokilammi A, Heikkinen PT, Iljin K, Kallioniemi OP, Jones FE, Jaakkola PM, Elenius K.

J Biol Chem. 2012 Mar 23;287(13):9659-71. doi: 10.1074/jbc.M111.299537. Epub 2012 Feb 3.

17.

Expression of HER2 in Breast Cancer Promotes a Massive Reorganization of Gene Activity and Suggests a Role for Epigenetic Regulation.

Rahmatpanah F, Jia Z, Chen X, Jones FE, McClelland M, Mercola D.

J Data Mining Genomics Proteomics. 2012;3. pii: e102. No abstract available.

18.

Jumonji/ARID1 B (JARID1B) protein promotes breast tumor cell cycle progression through epigenetic repression of microRNA let-7e.

Mitra D, Das PM, Huynh FC, Jones FE.

J Biol Chem. 2011 Nov 25;286(47):40531-5. doi: 10.1074/jbc.M111.304865. Epub 2011 Oct 3.

19.

The ERBB4 intracellular domain (4ICD) regulates NRG1-induced gene expression in hippocampal neurons.

Allison JG, Das PM, Ma J, Inglis FM, Jones FE.

Neurosci Res. 2011 Jun;70(2):155-63. doi: 10.1016/j.neures.2011.02.009. Epub 2011 Feb 23.

PMID:
21352860
20.

Neuregulin receptor ErbB4 functions as a transcriptional cofactor for the expression of surfactant protein B in the fetal lung.

Zscheppang K, Dörk T, Schmiedl A, Jones FE, Dammann CE.

Am J Respir Cell Mol Biol. 2011 Oct;45(4):761-7. doi: 10.1165/rcmb.2010-0179OC. Epub 2011 Feb 11.

21.

Downregulation of miR-342 is associated with tamoxifen resistant breast tumors.

Cittelly DM, Das PM, Spoelstra NS, Edgerton SM, Richer JK, Thor AD, Jones FE.

Mol Cancer. 2010 Dec 20;9:317. doi: 10.1186/1476-4598-9-317.

22.

Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen-activated protein kinase signaling pathway.

Mao L, Yuan L, Slakey LM, Jones FE, Burow ME, Hill SM.

Breast Cancer Res. 2010;12(6):R107. doi: 10.1186/bcr2794. Epub 2010 Dec 17.

23.

Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors.

Cittelly DM, Das PM, Salvo VA, Fonseca JP, Burow ME, Jones FE.

Carcinogenesis. 2010 Dec;31(12):2049-57. doi: 10.1093/carcin/bgq192. Epub 2010 Sep 27.

24.

Reactivation of epigenetically silenced HER4/ERBB4 results in apoptosis of breast tumor cells.

Das PM, Thor AD, Edgerton SM, Barry SK, Chen DF, Jones FE.

Oncogene. 2010 Sep 16;29(37):5214-9. doi: 10.1038/onc.2010.271. Epub 2010 Jul 5.

25.

The ERalpha coactivator, HER4/4ICD, regulates progesterone receptor expression in normal and malignant breast epithelium.

Rokicki J, Das PM, Giltnane JM, Wansbury O, Rimm DL, Howard BA, Jones FE.

Mol Cancer. 2010 Jun 15;9:150. doi: 10.1186/1476-4598-9-150.

26.

Subcellular localization of the HER4 intracellular domain, 4ICD, identifies distinct prognostic outcomes for breast cancer patients.

Thor AD, Edgerton SM, Jones FE.

Am J Pathol. 2009 Nov;175(5):1802-9. doi: 10.2353/ajpath.2009.090204. Epub 2009 Oct 1.

27.

An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance.

Mitra D, Brumlik MJ, Okamgba SU, Zhu Y, Duplessis TT, Parvani JG, Lesko SM, Brogi E, Jones FE.

Mol Cancer Ther. 2009 Aug;8(8):2152-62. doi: 10.1158/1535-7163.MCT-09-0295. Epub 2009 Aug 11.

28.

The HER4/4ICD estrogen receptor coactivator and BH3-only protein is an effector of tamoxifen-induced apoptosis.

Naresh A, Thor AD, Edgerton SM, Torkko KC, Kumar R, Jones FE.

Cancer Res. 2008 Aug 1;68(15):6387-95. doi: 10.1158/0008-5472.CAN-08-0538.

29.

HER4 intracellular domain (4ICD) activity in the developing mammary gland and breast cancer.

Jones FE.

J Mammary Gland Biol Neoplasia. 2008 Jun;13(2):247-58. doi: 10.1007/s10911-008-9076-6. Epub 2008 May 13. Review.

30.

The epidermal growth factor family of ligands and receptors grows and grows.

Gullick WJ, Jones FE.

J Mammary Gland Biol Neoplasia. 2008 Jun;13(2):157. doi: 10.1007/s10911-008-9085-5. Epub 2008 May 8. No abstract available.

PMID:
18463793
31.

Expression of tumor necrosis factor alpha converting enzyme in endocrine cancers.

Kirkegaard T, Naresh A, Sabine VS, Tovey SM, Edwards J, Dunne B, Cooke TG, Jones FE, Bartlett JM.

Am J Clin Pathol. 2008 May;129(5):735-43. doi: 10.1309/N6YB6YDVF58YCNHN.

PMID:
18426733
32.

Coregulation of estrogen receptor by ERBB4/HER4 establishes a growth-promoting autocrine signal in breast tumor cells.

Zhu Y, Sullivan LL, Nair SS, Williams CC, Pandey AK, Marrero L, Vadlamudi RK, Jones FE.

Cancer Res. 2006 Aug 15;66(16):7991-8.

33.

A constitutively active ERBB4/HER4 allele with enhanced transcriptional coactivation and cell-killing activities.

Vidal GA, Clark DE, Marrero L, Jones FE.

Oncogene. 2007 Jan 18;26(3):462-6. Epub 2006 Jul 10.

PMID:
16832345
34.

The ERBB4/HER4 intracellular domain 4ICD is a BH3-only protein promoting apoptosis of breast cancer cells.

Naresh A, Long W, Vidal GA, Wimley WC, Marrero L, Sartor CI, Tovey S, Cooke TG, Bartlett JM, Jones FE.

Cancer Res. 2006 Jun 15;66(12):6412-20.

36.
37.

ERBB4/HER4 potentiates STAT5A transcriptional activity by regulating novel STAT5A serine phosphorylation events.

Clark DE, Williams CC, Duplessis TT, Moring KL, Notwick AR, Long W, Lane WS, Beuvink I, Hynes NE, Jones FE.

J Biol Chem. 2005 Jun 24;280(25):24175-80. Epub 2005 Apr 29.

38.

Presenilin-dependent gamma-secretase processing regulates multiple ERBB4/HER4 activities.

Vidal GA, Naresh A, Marrero L, Jones FE.

J Biol Chem. 2005 May 20;280(20):19777-83. Epub 2005 Mar 3.

39.

The ERBB4/HER4 receptor tyrosine kinase regulates gene expression by functioning as a STAT5A nuclear chaperone.

Williams CC, Allison JG, Vidal GA, Burow ME, Beckman BS, Marrero L, Jones FE.

J Cell Biol. 2004 Nov 8;167(3):469-78.

40.
41.

ErbB4 signaling during breast and neural development: novel genetic models reveal unique ErbB4 activities.

Jones FE, Golding JP, Gassmann M.

Cell Cycle. 2003 Nov-Dec;2(6):555-9. Review.

PMID:
14504474
42.

Impaired differentiation and lactational failure of Erbb4-deficient mammary glands identify ERBB4 as an obligate mediator of STAT5.

Long W, Wagner KU, Lloyd KC, Binart N, Shillingford JM, Hennighausen L, Jones FE.

Development. 2003 Nov;130(21):5257-68. Epub 2003 Sep 3.

43.

Synthesis and characterization of PtSn/carbon and Pt3Sn/carbon nanocomposites as methanol electrooxidation catalysts.

Jones FE 3rd, Milne SB, Gurau B, Smotkin ES, Stock SR, Lukehart CM.

J Nanosci Nanotechnol. 2002 Feb;2(1):81-7.

PMID:
12908325
44.

The breast proto-oncogene, HRGalpha regulates epithelial proliferation and lobuloalveolar development in the mouse mammary gland.

Li L, Cleary S, Mandarano MA, Long W, Birchmeier C, Jones FE.

Oncogene. 2002 Jul 25;21(32):4900-7.

45.
46.

Weakly coordinating anions: crystallographic and NQR studies of halogen-metal bonding in silver, thallium, sodium, and potassium halomethanesulfonates.

Wulfsberg G, Parks KD, Rutherford R, Jackson DJ, Jones FE, Derrick D, Ilsley W, Strauss SH, Miller SM, Anderson OP, Babushkina TA, Gushchin SI, Kravchenko EA, Morgunov VG.

Inorg Chem. 2002 Apr 22;41(8):2032-40.

PMID:
11952356
47.
48.
50.

Impairment ratings and disability issues of the upper extremity.

Jones FE.

J Back Musculoskelet Rehabil. 1997 Jan 1;8(1):9-17. doi: 10.3233/BMR-1997-8105.

PMID:
24572712

Supplemental Content

Loading ...
Support Center